InflaRx NV (IFRX)

InflaRx (IFRX) Stock Price & Analysis


IFRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.57 - $7.25
Previous Close$3.06
Average Volume (3M)175.60K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)€16.27M
Total Debt (Recent Filing)€1.36M
Price to Earnings (P/E)-4.9
Mar 21, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding54,115,530
10 Day Avg. Volume98,888
30 Day Avg. Volume175,603
Standard Deviation0.33
Financial Highlights & Ratios
Price to Book (P/B)4.32
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside210.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $1.57 and its highest was $7.25 in the past 12 months.
    What is InflaRx NV’s market cap?
    Currently, no data Available
    When is InflaRx NV’s upcoming earnings report date?
    InflaRx NV’s upcoming earnings report date is Mar 21, 2024 which is in 176 days.
      How were InflaRx NV’s earnings last quarter?
      InflaRx NV released its earnings results on Aug 10, 2023. The company reported -$0.148 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.182.
        Is InflaRx NV overvalued?
        According to Wall Street analysts InflaRx NV’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does InflaRx NV pay dividends?
          InflaRx NV does not currently pay dividends.
          What is InflaRx NV’s EPS estimate?
          InflaRx NV’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does InflaRx NV have?
          InflaRx NV has 58,883,270 shares outstanding.
            What happened to InflaRx NV’s price movement after its last earnings report?
            InflaRx NV reported an EPS of -$0.148 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 9.589%.
              Which hedge fund is a major shareholder of InflaRx NV?
              Among the largest hedge funds holding InflaRx NV’s share is Woodline Partners LP. It holds InflaRx NV’s shares valued at 2M.


                InflaRx Stock Smart Score

                The InflaRx stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                InflaRx NV

                InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.


                Top 5 ETFs holding IFRX

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold IFRX. The ETFs are listed according to market value of IFRX within the ETF

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Corvus Pharmaceuticals
                Atara Biotherapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis